Effect of β-blocker therapy on the level soluble ST2 protein in the blood serum in patients with heart failure with preserved and mildly reduced ejection fraction

Aim. To study the prognostic value of high serum concentration of soluble ST2 protein (sST2) in the development of cardiovascular events after endovascular myocardial revascularization and the possibility of using this biomarker as a target for β-blocker therapy in patients with chronic heart failure (CHF) with preserved (HFpEF) and mildly reduced (HFmrEF) left ventricular ejection fraction.

Materials and methods. The study included 72 patients (aged 57–69 years, 81.94% were men) with class I–III CHF of ischemic etiology with HFpEF and HFmrEF. The patients were admitted to the cardiology department for endovascular myocardial revascularization. Before myocardial revascularization, serum concentrations of sST2 and N-terminal pro-brain natriuretic peptide (NT-proBNP) in all patients were analyzed by enzyme-linked immunosorbent assay (ELISA). Doses of β-blockers used in all patients were recalculated into a total daily dose equivalent to metoprolol succinate. Patients were divided into 2 groups depending on the median equivalent dose of metoprolol succinate (“high” ≥ 100 mg / day and “low” < 100 mg / day).

Results. In patients of group 1, the serum concentration of sST2 was 30.7% higher (p < 0.001) than in patients of group 2 (40.26 [34.39; 48.92] ng /ml and 27.9 [23.05; 35.27] ng / ml, respectively), the serum NT-proBNP level in group 1 was 22.8% higher (p = 0.049) than in group 2 (167 [129; 330] ng / ml vs. 129 [125; 147] ng / ml, respectively). In patients receiving an equivalent dose of metoprolol succinate < 100 mg / day, the incidence of cardiovascular events was 34% higher (p = 0.002) than in patients receiving an equivalent dose of metoprolol succinate ≥ 100 mg/day. The ROC analysis showed that serum sST2 level ≥ 34.18 ng / ml (sensitivity 78.0%, specificity 90.0%, area under the curve (AUC) 0.906; p < 0.0001) predicts a high risk of cardiovascular events within one year. However, the serum NT-proBNP level was not an informative predictor of cardiovascular events. 

Conclusion. It was confirmed that increased sST2 serum concentration has high prognostic value in the development of cardiovascular events within a year after endovascular myocardial revascularization. The possibility of using this biomarker as a target for β-blocker therapy in patients with HFpHF and HFmrEF was substantiated. Aggressive use of β-blockers in the group of patients with HFpEF and HFmrEF and sST2 overexpression is preferable in order to reduce the incidence of cardiovascular events.

1. Benjamin E.J., Blaha M.J., Chiuve S.E., Cushman M., Das S.R., Deo R. et al. Оn behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics − 2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603. DOI: 10.1161/CIR.0000000000000485.

2. Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016;21(8):7−13. DOI: 10.15829/1560-4071-2016-8-7-13.

3. Ponikowski P., Anker S.D., AlHabib K.F., Cowie M.R., Force T.L., Hu S. et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1(1):4−25. DOI: 10.1002/ehf2.12005.

4. Bayes-Genis A., Antonio M., Vila J., Peñafiel J., Galán A., Barallat J. et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J. Am. Coll. Cardiol. 2014;63(2):158–166. DOI: 10.1016/j.jacc.2013.07.087.

5. Калюжин В.В., Тепляков А.Т., Беспалова И.Д., Калюжина Е.В., Терентьева Н.Н., Сибирева О.Ф. др. Прогрессирующая (advanced) сердечная недостаточность. Бюллетень сибирской медицины. 2021;20(1):129−146. DOI: 10.20538/1682-0363-2021-1-129-146.

6. Luis S.A., Chan J., Pellikka P.A. Echocardiographic assessment of left ventricular systolic function: an overview of contemporary techniques, including speckle-tracking echocardiography. Mayo Clin. Proc. 2019;94(1):125−138. DOI: 10.1016/j.mayocp.2018.07.017.

7. Pfeffer M.A., Shah A.M., Borlaug B.A. Heart failure with preserved ejection fraction in perspective. Circ. Res. 2019; 124(11):1598−1617. DOI: 10.1161/CIRCRESAHA.119.313572.

8. Калюжин В.В., Тепляков А.Т., Рязанцева Н.В., Вечерский Ю.Ю., Хлапов А.П., Колесников Р.Н. Диастола сердца. Физиология и клиническая патофизиология. Томск: Изд-во ТПУ, 2007:212.

9. Heidenreich P.A., Albert N.M., Allen L.A., Bluemke D.A., Butler J., Fonarow G.C. et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ. Heart Fail. 2013;6(3):606–619. DOI: 10.1161/HHF.0b013e318291329a.

10. Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. 2006;355(3):251−259. DOI: 10.1056/NEJMoa052256.

11. Paulus W.J., Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 2013;62(4):263−271. DOI: 10.1016/j.jacc.2013.02.092.

12. Bratia R.S., Tu J.V., Lee D.S. Outcome of heart failure with preserved ejection fraction in a population-based study. N. Engl. J. Med. 2006;355(3):260–269. DOI: 10.1056/NEJMoa051530.

13. Гаврюшина С.В., Агеев Ф.Т. Сердечная недостаточность с сохраненной фракцией выброса левого желудочка: эпидемиология, «портрет» больного, клиника, диагностика. Кардиология. 2018;58(4S):55−64. DOI: 10.18087/cardio.2467.

14. Manzano-Fernandez S., Mueller T., Pascual-Figal D. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am. J. Cardiol. 2011;107(2):259−267. DOI: 10.1016/j.amjcard.2010.09.011.

15. Chatterjee S., Biondi-Zoccai G., Abbate A., D’Ascenzo F., Castagno D., Van Tassell B. et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013;346:f55. DOI: 10.1136/bmj.f55.

16. Тепляков А.Т., Попов С.В., Калюжин В.В., Гарганеева А.А., Курлов И.О., Нилогов В.Л. и др. Оценка влияния карведилола, атенолола и их комбинации с фозиноприлом на вариабельность ритма сердца, клинико-функциональный статус и качество жизни больных с постинфарктной дисфункцией левого желудочка. Терапевтический архив. 2004;76(9):62−65.

17. Borlaug B.A., Olson T.P., Lam C.S., Flood K.S., Lerman A., Johnson B.D. et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J. Am. Coll. Cardiol. 2010;56(11):845−854. DOI: 10.1016/j.jacc.2010.03.077.

18. Weir R.A.P., Miller A.M., Murphy G.E.J., Clements S., Steedman T., Connell J.M.C. et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J. Am. Coll. Cardiol. 2010;55(3):243−250. DOI: 10.1016/j.jacc.2009.08.047.

19. Калюжин В.В., Тепляков А.Т., Соловцов М.А. Роль систолической и диастолической дисфункции левого желудочка в клинической манифестации хронической сердечной недостаточности у больных, перенесших инфаркт миокарда. Терапевтический архив. 2002;74(12):15−18.

20. Abbate A., Arena R., Abouzaki N., Van Tassell B.W., Canada J., Shah K. et al. Heart failure with preserved ejection fraction: refocusing on diastole. Int. J. Cardiol. 2015;179:430−440. DOI: 10.1016/j.ijcard.2014.11.106.

21. Shah R.V., Chen-Tournoux A.A., Picard M.H., van Kimmenade R.R., Januzzi J.L. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ. Heart Fail. 2009;2(4):311–319. DOI: 10.1161/CIRCHEARTFAILURE.108.833707.

22. Ky B., French B., McCloskey K., Rame J.E., McIntosh E., Shahi P. et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ. Heart Fail. 2011;4(2):180−187. DOI: 10.1161/CIRCHEARTFAILURE.110.958223.

23. Останко В.Л., Калачева Т.П., Калюжина Е.В., Лившиц И.К., Шаловай А.А., Черногорюк Г.Э. и др. Биологические маркеры в стратификации риска развития и прогрессирования сердечно-сосудистой патологии: настоящее и будущее. Бюллетень сибирской медицины. 2018;17(4):264−280.

24. Дылева Ю.А., Груздева О.В., Акбашева О.Е., Учасова Е.Г., Федорова Н.В., Чернобай А.Г. и др. Значение стимулирующего фактора роста ST2 и NT-proBNP в оценке постинфарктного ремоделирования сердца. Российский кардиологический журнал. 2015;(12):63−71. DOI: 10.15829/1560-4071-2015-12-63-71.

25. Boisot S., Beede J., Isakson S., Chiu A., Clopton P., Januzzi J. et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J. Card. Fail. 2008;14(9):732–738. DOI: 10.1016/j.cardfail.2008.06.415.

26. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G., Coats A.J. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 2016;18(8):891−975. DOI: 10.1002/ejhf.592.

27. Prijic S., Buchhorn R. Mechanisms of beta-blockers action in patients with heart failure. Rev. Recent. Clin. Trials. 2014;9(2):58–60. DOI: 10.1007/s003950070004.

28. Fukuta H., Goto T., Wakami K., Kamiya T, Ohte N. Effect of beta-blockers on heart failure severity in patients with heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Heart Fail. Rev. 2021;26(1):165–171. DOI: 10.1007/s10741-020-10013-5

29. Colucci W.S. Molecular and cellular mechanisms of myocardial failure. Am. J. Cardiol. 1997;80(11A):15L–25L. DOI: 10.1016/s0002-9149(97)00845-x.

30. Калюжин В.В., Тепляков А.Т., Соловцов М.А., Калюжина Е.В., Беспалова И.Д., Терентьева Н.Н. Ремоделирование левого желудочка: один или несколько сценариев? Бюллетень сибирской медицины. 2016;15(4):120−139. DOI: 10.20538/1682-0363-2016-4-120-139.

31. Bavishi C., Chatterjee S., Ather S., Patel D., Messerli F.H. Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Fail Rev. 2015;20(2):193−201. DOI: 10.1007/s10741-014-9453-8.

32. Packer M., Fowler M.B., Roecker E.B., Coats A.J., Katus H.A., Krum H. et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194–2199. DOI: 10.1161/01.cir.0000035653.72855.bf.

33. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007.

34. Nguyen T., Shaheed A., Venigalla S., Mullokandov E. Using beta-blockers to treat heart failure. JAAPA. 2014;27(12):50–55. DOI: 10.1097/01.JAA.0000450813.21330.ee.

35. Bølling R., Scheller N.M., Køber L., Poulsen H.E., Gislason G.H., Torp-Pedersen C. Comparison of the clinical outcome of different beta-blockers in heart failure patients: a retrospective nationwide cohort study. Eur. J. Heart Fail. 2014;16(6):678–684. DOI: 10.1002/ejhf.81.

36. Pascual-Figal D.A., Lax A., Perez-Martinez M.T., del Carmen Asensio-Lopez M., Sanchez-Mas J. Clinical relevance of sST2 in cardiac diseases. Clin. Chem. Lab. Med. 2016;54(1):29–35. DOI: 10.1515/cclm-2015-0074.

37. Weinberg E.O., Shimpo M., De Keulenaer G.W., MacGillivray C., Tominaga S., Solomon S.D. et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106(23):2961–2966. DOI:10.1161/01.CIR.0000038705.69871.D9.

38. Тепляков А.Т., Тарасов Н.И., Исаков Л.К., Гракова Е.В., Синькова М.Н., Копьева К.В. др. Прогноз сердечно-сосудистых событий после имплантации кардиовертера-дефибриллятора пациентам с хронической сердечной недостаточностью: значение повышения концентрации эндотелина-1 и растворимой формы белка ST2 в плазме крови. Бюллетень сибирской медицины. 2018;17(3):140–150. DOI: 10.20538/1682-0363-2018-3-140-150.

39. Kakkar R., Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat. Rev. Drug. Discov. 2008;7(10):827−840. DOI: 10.1038/nrd2660.

40. Копьева К.В., Тепляков А.Т., Гракова Е.В., Солдатенко М.В., Огуркова О.Н., Ахмедов Ш.Д. Роль нового биомаркера ST2 в оценке ремоделирования миокарда у больных хронической сердечной недостаточностью ишемического генеза с сохраненной фракцией выброса левого желудочка. Кардиология. 2018;58(10S):33−43. DOI: 10.18087/cardio.2498.

41. Xia J., Qu Y., Yin C., Xu D. Preliminary study of beta-blocker therapy on modulation of interleukin-33/ST2 signaling during ventricular remodeling after acute myocardial infarction. Cardiol. J. 2017;24(2):188−194. DOI: 10.5603/CJ.a2016.0096.

42. Gaggin H.K., Motiwala S., Bhardwaj A., Parks K.A., Januzzi J.L.Jr. Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure. Circ. Heart Fail. 2013;6 (6):1206−1213. DOI: 10.1161/CIRCHEARTFAILURE.113.000457.

43. Huang W.P., Zheng X., He L., Su X., Liu C.W., Wu M.X. Role of soluble ST2 levels and beta-blockers dosage on cardiovascular events of patients with unselected st-segment elevation myocardial infarction. Chin. Med. J. (Engl.). 2018;131(11):1282−1288. DOI: 10.4103/0366-6999.232819.